Wang J, Wang M, Zeng X, Li Y, Lei L, Chen C
Cell Commun Signal. 2025; 23(1):89.
PMID: 39955542
PMC: 11830217.
DOI: 10.1186/s12964-025-02089-z.
Ramzy G, Meister I, Rudaz S, Boccard J, Nowak-Sliwinska P
Int J Mol Sci. 2025; 26(3).
PMID: 39940937
PMC: 11818583.
DOI: 10.3390/ijms26031169.
Su Z, Liu M, Krohn M, Schwarz S, Linnebacher M
Apoptosis. 2025; .
PMID: 39904858
DOI: 10.1007/s10495-025-02084-2.
Karbanova J, Thamm K, Fargeas C, Deniz I, Lorico A, Corbeil D
J Nanobiotechnology. 2025; 23(1):61.
PMID: 39881297
PMC: 11776279.
DOI: 10.1186/s12951-025-03102-w.
Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y
Int J Mol Med. 2025; 55(3).
PMID: 39820715
PMC: 11759585.
DOI: 10.3892/ijmm.2025.5487.
Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis.
Xing Z, Ma Y, Jiang X, Qing H, Wu Y, Che S
Med Oncol. 2024; 42(1):9.
PMID: 39565443
PMC: 11579105.
DOI: 10.1007/s12032-024-02557-5.
Targeting Lipid Metabolism in Cancer Stem Cells for Anticancer Treatment.
Singh M, Han S, Kim S, Kang I
Int J Mol Sci. 2024; 25(20).
PMID: 39456967
PMC: 11508222.
DOI: 10.3390/ijms252011185.
Metabolomics of 3D cell co-culture reveals alterations in energy metabolism at the cross-talk of colorectal cancer-adipocytes.
Pelosi A, Silva A, Fernandes A, Scariot P, Oliveira M, M Porcari A
Front Med (Lausanne). 2024; 11:1436866.
PMID: 39421865
PMC: 11484090.
DOI: 10.3389/fmed.2024.1436866.
Causal effects and metabolites mediators between immune cell and risk of colorectal cancer: a Mendelian randomization study.
Yang Q, Duan B, Yue J, Zhang D, Chen X, Shi M
Front Immunol. 2024; 15:1444222.
PMID: 39346920
PMC: 11428109.
DOI: 10.3389/fimmu.2024.1444222.
Association of COX-inhibitors with cancer patients' survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis.
Flausino L, Ferreira I, Tuan W, Estevez-Diz M, Chammas R
Front Oncol. 2024; 14:1433497.
PMID: 39346725
PMC: 11427433.
DOI: 10.3389/fonc.2024.1433497.
Harnessing Interactional Sensory Genes for Rationally Reprogramming Chaotic Metabolism.
Tan C, Xu P, Tao F
Research (Wash D C). 2024; 2022:0017.
PMID: 39290971
PMC: 11407584.
DOI: 10.34133/research.0017.
Lipid droplets and small extracellular vesicles: More than two independent entities.
Genard G, Tirinato L, Pagliari F, Da Silva J, Giammona A, Alquraish F
J Extracell Biol. 2024; 3(9):e162.
PMID: 39257626
PMC: 11386333.
DOI: 10.1002/jex2.162.
Lipid metabolism associated crosstalk: the bidirectional interaction between cancer cells and immune/stromal cells within the tumor microenvironment for prognostic insight.
Lin Z, Hua G, Hu X
Cancer Cell Int. 2024; 24(1):295.
PMID: 39174964
PMC: 11342506.
DOI: 10.1186/s12935-024-03481-4.
The role of lysophosphatidylcholine acyltransferase 2 in osteoblastic differentiation of C2C12 cells.
Tabe S, Hikiji H, Hashidate-Yoshida T, Shindou H, Shimizu T, Tominaga K
FEBS Open Bio. 2024; 14(9):1490-1502.
PMID: 39075841
PMC: 11492341.
DOI: 10.1002/2211-5463.13845.
Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/BRAF metastatic colorectal cancer-specific survival.
Xiang Y, Zhang C, Wang J, Cheng Y, Wang K, Wang L
Int J Colorectal Dis. 2024; 39(1):116.
PMID: 39046546
PMC: 11269474.
DOI: 10.1007/s00384-024-04686-9.
Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20/CCR6 axis in human hepatocellular carcinoma.
Wang Y, Chen W, Qiao S, Zou H, Yu X, Yang Y
Cell Mol Immunol. 2024; 21(10):1120-1130.
PMID: 38942796
PMC: 11443046.
DOI: 10.1038/s41423-024-01199-x.
Multimodal Phasor Approach to study breast cancer cells invasion in 3D spheroid model.
Tedeschi G, Palomba F, Scipioni L, Digman M
bioRxiv. 2024; .
PMID: 38915530
PMC: 11195137.
DOI: 10.1101/2024.06.10.598307.
Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases.
Korbecki J, Bosiacki M, Pilarczyk M, Gassowska-Dobrowolska M, Jarmuzek P, Szucko-Kociuba I
Cancers (Basel). 2024; 16(11).
PMID: 38893234
PMC: 11171337.
DOI: 10.3390/cancers16112115.
Targeting lipid reprogramming in the tumor microenvironment by traditional Chinese medicines as a potential cancer treatment.
Zuo Q, Wu Y, Hu Y, Shao C, Liang Y, Chen L
Heliyon. 2024; 10(9):e30807.
PMID: 38765144
PMC: 11101863.
DOI: 10.1016/j.heliyon.2024.e30807.
A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance.
Das C, Bhattacharya A, Adhikari S, Mondal A, Mondal P, Adhikary S
Oncogene. 2024; 43(23):1727-1741.
PMID: 38719949
PMC: 11161412.
DOI: 10.1038/s41388-024-03054-9.